Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chai, Xinqun ^a   Chu, Hongpeng ^a   Yang, Xuan ^a   Meng, Yuanpu ^a   Shi, Pengfei ^b   Gou, Shanmiao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; DEOXYCYTIDINE; GEMCITABINE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; S6 KINASE;

ANALOGS AND DERIVATIVES; ANIMAL; CANCER STEM CELL; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MORTALITY; MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AC133 ANTIGEN; ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HUMANS; METFORMIN; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES; PHOSPHORYLATION; PROGNOSIS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942134312     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14404     Document Type: Article

References (54)

1. Andriulli, A. et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann. Surg. Oncol. 19, 1644-1662 (2012).
2. Davis, J. L., Pandalai, P. K., Ripley, R. T., Langan, R. C. & Avital, I. Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy. Pancreas 41, 678-684 (2012).
3. Dragovich, T. Is there a case for personalized therapy of pancreatic cancer? Clin. Adv. Hematol. Oncol. 10, 344-345 (2012).
4. Poruk, K. E., Firpo, M. A., Adler, D. G. & Mulvihill, S. J. Screening for pancreatic cancer: why, how, and who? Ann. Surg. 257, 17-26 (2013).
5. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
6. Tempero, M. A. et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J. Natl. Compr. Canc. Netw. 10, 703-713 (2012).
7. Burris, H. A., 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
8. Grunewald, R., Abbruzzese, J. L., Tarassoff, P. & Plunkett, W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 27, 258-262 (1991).
9. Ren, C., Chen, H., Han, C., Wang, D. & Fu, D. Increased plasma microRNA and CD133/CK18-positive cancer cells in the pleural fluid of a pancreatic cancer patient with liver and pleural metastases and correlation with chemoresistance. Oncol. Lett. 4, 691-694 (2012).
10. Hayashi, T. et al. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Cancer Sci. 103, 889-896 (2012).
11. Zhang, S. N., Huang, F. T., Huang, Y. J., Zhong, W. & Yu, Z. Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. Tumori. 96, 985-992 (2010).
12. Gou, S. et al. Low concentrations of metformin selectively inhibit CD133(+ ) cell proliferation in pancreatic cancer and have anticancer action. PLoS One 8, e63969 (2013).
13. Robitaille, A. M. et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-1323 (2013).
14. Morran, D. C. et al. Targeting mTOR dependency in pancreatic cancer. Gut 63, 1481-1489 (2014).
15. Van Laethem, J. L. et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J. Clin. Oncol. 28, 4450-4456 (2010).
16. Vermeulen, L., Melo, F. D. E., Richel, D. J. & Medema, J. P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncology 13, E83-E89 (2012).
17. Fillmore, C. M. & Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Research 10, R25, doi: 10.1186/Bcr1982 (2008).
18. Ghods, A. J. et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25, 1645-1653 (2007).
19. Wurth, R. et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 12, 145-156 (2013).
20. Janzer, A. et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc. Natl. Acad. Sci. USA 111, 10574-10579 (2014).
21. Kirpichnikov, D., McFarlane, S. I. & Sowers, J. R. Metformin: an update. Ann. Intern. Med. 137, 25-33 (2002).
22. Sadeghi, N., Abbruzzese, J. L., Yeung, S. C., Hassan, M. & Li, D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 18, 2905-2912 (2012).
23. Wolff, R. A. Chemoprevention for pancreatic cancer. Int. J. Gastrointest. Cancer 33, 27-41 (2003).
24. Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M. & Abbruzzese, J. L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137, 482-488 (2009).
25. Gou, S. M. et al. Low Concentrations of Metformin Selectively Inhibit CD133(+ ) Cell Proliferation in Pancreatic Cancer and Have Anticancer Action. Plos One 8, e63969, doi: 10.1371/journal.pone.0063969 (2013).
26. Gou, S. et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 34, 429-435 (2007).
27. Rozengurt, E., Sinnett-Smith, J. & Kisfalvi, K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G proteincoupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16, 2505-2511 (2010).
28. Ming, M. et al. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS One 9, e114573 (2014).
29. Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390-401 (2010).
30. Ben Sahra, I. et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372 (2011).
31. Malki, A. & Youssef, A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol. Res. 19, 275-285 (2011).
32. Jalving, M. et al. Metformin: taking away the candy for cancer? Eur. J. Cancer 46, 2369-2380 (2010).
33. Bao, B. et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila) 5, 355-364 (2012).
34. Tanaka, R., Tomosugi, M., Horinaka, M., Sowa, Y. & Sakai, T. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. PLoS One 10, e0125779 (2015).
35. Lonardo, E. et al. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 8, e76518 (2013).
36. Mohammed, A. et al. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl. Oncol. 6, 649-659 (2013).
37. Chen, G., Nicula, D., Renko, K. & Derwahl, M. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol. Rep. 33, 1994-2000 (2015).
38. Ling, S. et al. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol. Rep. 31, 2611-2618 (2014).
39. Jeong, J. H. et al. Ascochlorin inhibits growth factor-induced HIF-1alpha activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells. J. Cell Biochem. 113, 1302-1313 (2012).
40. Bessard, A., Fremin, C., Ezan, F., Coutant, A. & Baffet, G. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J. Cell Physiol. 212, 526-536 (2007).
41. Li, S. H. et al. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Surgery 157, 570-580 (2015).
42. Viollet, B. et al. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond) 122, 253-270 (2012).
43. Han, G., Gong, H., Wang, Y., Guo, S. & Liu, K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformininduced apoptosis in human gastric cancer cell. Cancer Biol. Ther. 16, 77-87 (2015).
44. Nair, V. et al. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J. Biol. Chem. 289, 27692-27701 (2014).
45. Schuler, K. M. et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 4, 161-173 (2015).
46. Vujic, I. et al. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget 6, 969-978 (2015).
47. Han, S., Li, Z., Master, L. M., Master, Z. W. & Wu, A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. Br. J. Cancer 111, 1400-1409 (2014).
48. Liu, Y. et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncol. Lett. 8, 367-373 (2014).
49. Fernandez-Fuente, G., Mollinedo, P., Grande, L., Vazquez-Barquero, A. & Fernandez-Luna, J. L. Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors. Mol. Cancer. Ther. 13, 1664-1672 (2014).
50. Wang, M. et al. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. World J. Surg. Oncol. 13, 66 (2015).
51. Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
52. Soares, H. P., Ni, Y., Kisfalvi, K., Sinnett-Smith, J. & Rozengurt, E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. Plos One 8, e57289 (2013).
53. Choi, Y. et al. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Cancer Res. Treat, doi: 10.4143/crt.2014.292 (2015).
54. Utomo, W. K. et al. mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Lett. 346, 309-317 (2014).